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Global Drug Survey (GDS) 2016 Findings Released 
  
NPS trends and harms around the world- synthetic cannabinoids riskier than ever, the rise 
and rise of dark-net drug markets around the world, big increase in cocaine, MDMA and 
nitrous use among clubbers, better quality MDMA leading to more A&E admissions, nitrous 
oxide and nerve damage and why people should avoid drinking spirits key themes of 
GDS2016 
  
Global Drug Survey (GDS) runs the world's biggest drug survey and 
provides invaluable insight into the world's drug taking habits. For the second year 
running, more than 100,000 people from over 50 countries were surveyed.   GDS has 
a proven track record in being able to track trends over time, profile new drugs and 
identify key issues of relevance and importance to people who use drugs and those 
who craft public health and drug policy. GDS aims to help people and communities 
reduce the harm associated with drug use by sharing credible information.  
.  
Key findings from the Global Drug Survey2016 (data collected Nov 15-Jan 16) 
 
More people shopping on the dark net, more people using MDMA & experiencing 
harm, synthetic cannabinoids the most dangerous drugs in the world.  
 
Excluding alcohol, tobacco and caffeine products the top 10 drugs used across the 
world were  
 
Cannabis / MDMA / Cocaine / Amphetamines / LSD / Magic mushrooms / 
Prescribed / non prescribed opioid medications / Nitrous Oxide / Ketamine / Poppers 
Results of the world’s biggest drug survey 
launching on Tuesday June 14th in 20 countries  
Incorporated in England 7534181 
VAT Registration Number 1103 96 251 
  
Novel Psychoactive Substances (NPS) Trends in the UK – most people buy NPS 
on-line 
 
o UK has highest rate of last year NPS purchase of any GDS country (11.6% of UK 
sample)  
o GDS2016 reports increase in UK last year purchase of NPS after falling rates 
over last 4 years 
o Decline in high street NPS purchases from 46.3% in GDS2014 to 34.6% in 
GDS2016.   
o 58% of those reporting buying NPS last year did so on-line.   
o 3 times more likely end up seeking emergency medical treatment with NPS 
than traditional drugs 
 
Synthetic Cannabinoids (SCs) and A&E  
 
o Synthetic cannabinoids more likely to lead to emergency medical treatment 
than any other drug 
o 1 in 8 of those using weekly or more often reported seeking emergency medical 
treatment (3.5% of all users)  
o Overall risk of seeking emergency medical treatment when using SCs is 30 
times greater than skunk 
o Over half of those using more than 50 times in last year who tried to stop 
reported withdrawal symptoms  
 
The dark-net rising 
 
o Globally almost in 1 in 10 participants (9.3%) reported ever buying drugs off the 
dark-net with those reporting last year dark-net purchase rising from 4.5% to 
6.7%.   
o MDMA, cannabis, new or novel substances (including 2C-B and DMT) and LSD 
are the drugs most commonly bought 
o 5% of respondents stated that they did not consume drugs prior to accessing 
them through dark-net markets 
 
The worst time to be using MDMA in a generation 
 
o Increase in use of both MDMA and cocaine over the last 3 years.  
o Concerns over high dose MDMA pills leading to increased risk of acute harm 
o 4-fold increase in British female clubbers seeking emergency medical treatment 
in last 3 years. Women 2-3 more likely to seek emergency treatment than men 
o UK users take more MDMA in a night than anyone else (almost half a gram) 
o Most people use less than 10 times per year 
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o Less is more (more fun with less MDMA) 
 
 
No Laughing Matter 
o Biggest study of nitrous oxide use ever  
o Increasing rates of use in the UK and globally nitrous oxide is now ranked the 
7th most popular drug in the world.  
o 10% of users worried about impact of mental / physical health  
o 4% reporting symptoms of nerve damage due to vitamin B12 deficiency  
 
Drinkers 
o One third of drinkers would like to drink less in the coming year yet only 10% 
on average would like help to do so. www.drinksmeter.com and 
www.onetoomany.co might help people drink less. 
o Spirits best avoided on night out  
  
  
DETAILED FINDINGS at www.globaldrugsurvey.com from 9am BST June 14th  
NPS Trends in the UK and globally 
After a year on year decline in UK participants reporting buying any NPS in the last 
year from a high of 20% in GDS2012 to a low of 8.6% in GDS2015, this year the UK saw 
a rise in last year purchase to 11.6%, the highest rate of any country assessed. The 
next highest rates were found in the USA, Canada and surprisingly the Netherlands 
with the lowest rates in Switzerland. Globally the mean rate was 4.8%.  
 
58% of UK participants reporting buying NPS last year did so on-line.  Prior to the 
passing of the NPs Bill in May 2016, there had been increasing local efforts often 
spear headed by Trading Standards to close high street shops selling NPS products. 
Over the last 3 years GDS has reported a decline in high street purchase from 46.3% 
in GDS2014, 44.9% in GDS2015 to 34.6% in GDS2016.  Over the same time frame 
there has been an increase in buying them from a ‘dealer’ from 8.5% to 12.7%.  
 
Globally the top motivations for using NPS reflected the advantages of these products 
being legal - easy access to them on-line and price. Thinking these drugs were safer 
than illicit drugs was the lowest ranked factor - and indicates that people are not 
stupid and media myths of people think legal = safe is untrue.  
 
NITROUS OXIDE IS NO LAUGHING MATTER 
Discounting alcohol, caffeine and tobacco, nitrous oxide was ranked the 7th most 
popular drug in the world and the 4th most commonly used drug by UK clubbers 
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where rates among UK clubber have gone up from 34% to 39% to 48 % over the last 3 
years. 
More commonly known as laughing gas, nitrous oxide continues to be popular 
worldwide. The UK had the highest rates of nitrous oxide use, with over a third (34%) 
of all UK respondents reporting they had used laughing gas in the last year, The 
Netherlands came a close second. GDS2016 confirms findings from GDS2015 that 
heavy users of nitrous oxide were at serious risk of adverse mental and 
physical health problems. Findings showed 4% of users reported symptoms 
consistent with peripheral neuropathy, a serious disease due to inactivation of 
Vitamin B12 by nitrous oxide that affects the nerves, causing persistent numbness or 
tingling in their hands, feet or around their face or mouth.  
  
DRUGS AND THE DARK NET 
The dark net is booming with our 3 year trends showing increased rates of people 
buying drugs on the dark-net in virtually every country. Exit scams, where market 
owners close the market unexpectedly and steal the funds, have also become 
commonplace. Despite these disruptions, we have obtained a record sample of dark-
net drug buyers in GDS2016 (n=8058).  
 
Globally almost in 1 in 10 participants (9.3%) reported ever buying drug off the dark-
net with those reporting last year dark net purchase rising from 4.5% to 6.7%.  Drug 
policy and local drug markets exert significant influence over levels of dark-net 
involvement, with static low rates of less than 2% in Portugal and Switzerland to stable 
high rates above 20% in Sweden.  
 
This year we were also able to report trends in which drugs were bought through the 
dark-net. The results from 2016 were remarkably similar to 2015: with MDMA, 
cannabis, new or novel substances (including 2C-B and DMT) and LSD topping the list.  
As in previous years, while many people claimed that the range of drugs they used 
remained the same, around a third of dark-net drug buyers reported that they 
consumed a wider range than previously.  
 
This year, 5% of respondents stated that they did not consume drugs prior to 
accessing them through dark-net markets. Of the drugs purchased through dark-net 
markets the drugs most commonly reported as being used for the first time were 
MDMA followed by any NPS.  Among recent drug users, people who used the dark-net 
were younger, more likely to be male, more educated and less likely to be a regular 
clubber, than those who did not report using the dark-net. 
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SYNTHETIC CANNABINOIDS (SCs) MORE DANGEROUS THAN ANY OTHER DRUG  
Over the past 5 years the Global Drug Survey has conducted the largest studies in the 
world on synthetic cannabinoid products.  These remain a changing and very diverse 
group of drugs both in terms of risks and preparations. While smoking herbal 
preparations remained the most common form the drug used, 10% reported the use 
of powder, 7.5% resin and 3% oil/liquid.  
 
For the fourth year running they topped the list of drugs most likely to leave you 
needing emergency medical treatment, with over 1 in 30 last year users reporting 
seeking emergency medical treatment (4.2% of male users versus 2.4% of female 
users), rising to 1 in 8 of weekly or more frequent users.  GDS spotted that the rate of 
seeking emergency treatment following the use of SCs varies widely between 
countries, with highest rates (8-9% of all last year users) being seen in Australia and 
the US while the rates in Austria, Mexico and France were zero. The wide variation 
almost certainly reflects the different risks posed by the diverse potencies and actions 
of different SC compounds. Their inconsistent preparation means for most users 
there is no reliable way to know how much active product they are consuming. That 
only 3% of cannabis users on a fictional desert island with a good supply of fine 
natural cannabis said they would switch natural for synthetic cannabinoids shows just 
how unattractive these drugs are. 
 
Dependence and withdrawal are becoming an increasing issue 
Our findings suggest that these drugs typically lead to a quicker onset of a more 
intense but short lived effect compared to natural cannabis leading to the more rapid 
development of tolerance. This typical effect profile reported by over 1000 users of 
SCs who took part in GDS2016 explains the higher risks of developing dependence 
and withdrawal on these drugs, with over half of those who tried to stop reporting 
withdrawal symptoms.  
 
BETTER QUALITY MDMA IS NOT SAFER AND WHY MORE MDMA IS NOT MORE FUN 
 
2016 might be the worst time to start taking MDMA in a generation. MDMA has never 
been so plentiful and as GDS trend data shows, more and more people are using it, 
with last year use among UK clubbers increasing from 68% to 80%. The rising 
popularity of EDM and dispersion of MDMA from the dance floor to mainstream drug 
culture has coincided with resurgence of MDMA availability. In many countries high 
purity MDMA crystal now competes with high dose MDMA pills (in many parts of 
Europe the average dose of MDMA found in ecstasy pills is now 100-150mg/pill with 
doses over 300mg having been reported).  
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GDS has concerns that high dose pills and high purity MDMA powder across the EU is 
making it easy for people to take too much increasing the risk of harm and reducing 
enjoyment.  
GDS has recorded a 4-fold increase in British female clubbers seeking emergency 
medical treatment over the last 3 years from 0.4% to 1.6% with younger women most 
at risk. 90% of those seeking emergency medical treatment report the use of alcohol 
and other drugs in addition to MDMA 
Women 2-3 more likely to seek emergency treatment than men 
UK users take more MDMA (almost half a gram compared to a quarter of gram 
elsewhere) in a night than anyone else 
Most people use less than 10 times per year 
 
Please support our safer MDMA use campaign launching June 14  Don’t Be Daft Start 
With Half #StartWithHalf. We will send through a link to an animated health 
promotion video on Tuesday AM if you request it. 
Different beverage and different behaviours 
Despite some considerable national variation, it seems that spirits are the type of 
alcohol most commonly drunk when away from home and also rated most likely to 
make you feel energised, confident and sexy. Inconsistently, spirits were also rated as 
most likely to make you feel restless, tearful and ill (including most likely to give you a 
hangover). Beer was voted as most likely to make you feel relaxed and red wine 
topped the list for making you sleepy. The polarizing effects of spirits are most likely a 
consequence of dose and it’s more difficult to dose right with spirits. 
You can end up cool and sexy or pathetic and passed out on any form of alcohol. But 
if all the above is true then there appear to be advantages to avoiding spirits. Not 
because of the ‘alcohol’ necessarily having different effects but because spirits are 
highly concentrated, hard to titrate and keep track of and they can fool your body into 
thinking you have not yet drunk ‘enough’ when actually it is already sitting there 
waiting to be absorbed. All good reasons GDS would have thought to avoid shorts.  
  
From the founder of Global Drug Survey  
Dr Adam R Winstock, MD MRCP MRCPsychFAChAM, Consultant Psychiatrist & 
Addiction Medicine Specialist and founder of the Global Drug Survey comments: The 
world of drugs has changed for ever.  From what people use and how they use it to 
where they get it from the landscape has never been so varied and challenging for 
people who use drugs, health care providers and governments. More than ever 
ideological rhetoric and moralistic judgments on what substances people choose to 
use need to be replaced with a more honest narrative. Overall our data suggests that 
while traditional drugs retain their dominance and appear to carry less risk than their 
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novel synthetic counterparts, the NPS market continues to evolve. The risks of 
synthetic cannabinoids including dependence combined with huge profits and almost 
impossible task of significantly diminishing supply means the most marginalised will 
remain vulnerable to using them. Credible conversations that treat people as adults 
who want to stay happy and healthy and that accept that drugs can enhance a 
person’s life are needed. While nothing can ever reduce the risk to zero,  people can 
through their own actions significantly reduce that risk. The right conversation can 
change people’s lives for the better and help keep them safe. Drugs laws increase 
stigma and make it like less likely people will seek help or advice. Making drugs legal 
will never make them safe, but changing drugs laws may well be part of helping 
everyone have a more honest conversation.  GDS believes honesty is the best drug 
policy. For more information and advice on safer drug and alcohol use, 
visit www.drugsmeter.com and www.drinksmeter.com.  
- ENDS - 
For more information, please email the team at Claire@globaldrugsurvey.com 
or call her on 00447568186525 
  
Notes to editors 
About the Global Drug Survey 
 
Global Drug Survey (GDS) runs the world’s biggest drug survey. GDS is an independent 
global drug use data exchange hub that conducts university ethics approved, 
anonymous online surveys. We collaborate with global media partners who act as 
hubs to promote our work. Our last survey, GDS2016, ran for 6 weeks at the end of 
2015, was translated into 10 languages and received over 100,000 responses from 
around the world.  Over the last 3 years we have obtained data from over 300,000 
people. By the end of 2016 we estimate our global database to be in excess of 
600,000.  
GDS is comprised of experts from the fields of medicine, toxicology, public health, 
psychology, chemistry, public policy, criminology, sociology, harm reduction and 
addiction. We research key issues of relevance and importance to both people who 
use drugs and those who craft public health and drug policy. We publish 5-10 
academic articles per year.  
 
We aim to help people and communities reduce the harm associated with the use of 
drugs regardless of their legal status use by sharing information in a credible and 
meaningful way.  Identifying new drug trends among sentinel drug using populations 
allows pre-emptive service planning and informed policy development. Over the last 
decade these methods have successfully supported the widespread dissemination of 
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essential information both to people who use drugs through our media partners and 
to the medical profession through academic papers presentation at international 
conferences, expert advisory meetings and a range of free resources 
including www.drugsmeter.com and www.drinksmeter.com 
                 www.saferuselimits.com and www.onetoomany.com 
 
Methodology  
 
Don’t look to GDS for national estimates. GDS is designed to answer comparison 
questions that are not dependent on probability samples meaning our analyses are 
better suited to highlight differences among user populations and trends among 
subpopulations. GDS recruits younger, more involved drug using populations. We 
spot emerging drugs trends before they enter into the general population GDS can 
help add numbers and depth to the findings of more rigorous, though less detailed 
and smaller, survey findings GDS is an efficient approach to gain content rich data 
that explores diverse health outcomes associated with the use of drugs and alcohol 
across the population of your country.  
 
Our recruitment strategy is an example of purposive sampling. We acknowledge that 
this has significant limitations, most notably with respect to response bias whereby 
there will be inherent differences between those who participate and those who do 
not. It is more likely that individuals will respond to surveys if they see topics or items 
that are of interest to them, and thus by definition will differ from those who do not 
participate. Therefore, as participants in our survey may have a greater interest in or 
experience with drugs, they may not be representative of the wider population. 
However, purposive sampling that seeks to include a wide cross-section of users and 
a large overall sample size can result in a sample of drug users that may be 
considered sufficiently representative to make reasonable inferences for the general 
population. Importantly our approach accesses sections of the populations that 
general household surveys do not (e.g. students) and of course we are able to explore 
drug related in significantly more depth. Our sample size is also considerably bigger 
than most national household surveys. When judged against traditional 
epidemiological criteria for monitoring public health, GDS fully acknowledges that our 
methods have potentially significant limitations. These have been fully discussed in 
the academic publications that the GDS Academic Network produce each year.  
   
END   
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